Unicycive Therapeutics Inc • UNCY

Capital at risk.

About Unicycive Therapeutics Inc
Ticker
info
UNCY
Trading on
info
NASDAQ
ISIN
info
US90466Y1038
Industry
info
Biotechnology
Sector
info
Healthcare
CEO
info
Dr. Shalabh K. Gupta M.D., MPA
Headquarters
info
4300 El Camino Real, Los Altos, CA, United States, 94022
Employees
info
22
Website
info
https://unicycive.com
Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies to address unmet medical needs in the United States. Its drug candidates include UNI 494, a pro-drug of Nicorandil that is being developed as a treatment for acute kidney injury; and Renazorb RZB 012 for the treatment of hyperphosphatemia in patients with chronic kidney disease. The company also evaluates licensing of technologies and drugs for orphan diseases, other renal, liver, and other metabolic diseases affecting fibrosis and inflammation. Unicycive Therapeutics, Inc. has license agreements with Shilpa Medicare Ltd to develop and commercialize oxylanthanum carbonate; Sphaera Pharma Pte. Ltd.; Syneos Health LLC to develop of UNI-494; Inotiv for preclinical trial and related services for oxylanthanum carbonate and UNI-494; Lee's Pharmaceutical (HK) Limited; and Lotus International Pte Ltd for the development, registration filing, and approval for oxylanthanum carbonate. The company was incorporated in 2016 and is based in Los Altos, California.
Metrics
BasicAdvanced
Market cap
info
$124M
P/E ratio
info
-
EPS
info
-$3.44
Dividend Yield
info
0.00%
Beta
info
1.86
Forward P/E ratio
info
1.25
EBIDTA
info
$-31.5M
Ex dividend date
info
-
Price & volume
Market cap
info
$124M
Average daily volume
info
0.5M
90-day return
info
-
30-day return
info
-
7-day return
info
-
Dividends
Dividend per share
info
$0.00
Dividend yield
info
0.00%
Forward dividend per share
info
$0.00
Forward dividend yield
info
0.00%
Payout ratio
info
0.00%
Valuation
P/E ratio
info
0
Forward P/E
info
1.25
PEG ratio
info
-
Trailing P/E
info
0
Price to sales
info
23.75
Price to book
info
3.25
Earnings
EPS
info
-$3.44
EPS estimate (current quarter)
info
-$0.53
EPS estimate (next quarter)
info
-$0.56
EBITDA
info
$-31.5M
Revenues (TTM)
info
$0M
Revenues per share (TTM)
info
$0.00
Technicals
Beta
info
1.86
52-week High
info
$11.00
52-week Low
info
$3.71
50-day moving average
info
$4.54
200-day moving average
info
$5.30
Short ratio
info
2.77
Short %
info
7.12%
Management effectiveness
ROE (TTM)
info
-102.29%
ROA (TTM)
info
-44.22%
Profit margin
info
0.00%
Gross profit margin
info
$0M
Operating margin
info
0.00%
Growth
Quarterly earnings growth (YoY)
info
0.00%
Quarterly revenue growth (YoY)
info
0.00%
Share stats
Outstanding Shares
info
21.5M
Float
info
15.8M
Insiders %
info
2.93%
Institutions %
info
30.38%
Analyst Insights & forecasts
info

100% Buy

0% Hold

0% Sell

Based on information from 7 analysts.

Average price target

info
$46.52
Earnings per share (EPS) forecast
windowbar_chart_4_bars
Actual
info
Expected
info
Surprise
info
$0.25
-$0.09
373.52%
Q4 • 24Beat
-$0.50
-$0.10
-400.00%
Q1 • 25Missed
-$1.50
-$0.07
-2,042.86%
Q2 • 25Current
QuarterlyAnnual
Financial Performance
windowbar_chart_4_bars
Income StatementBalance SheetCash Flow
windowbar_chart_4_bars
Revenue
info
Net income
info
Profit margin
info
$0M
$-6.4M
-∞%
Q2 • 25
$0M
$-6M
-∞%
Q3 • 25
NaN%
-6.76%
NaN%
QoQ growth
QuarterlyAnnual
Totals assets
info
Total liabilities
info
Debt to assets
info
$30M
$13.6M
45.23%
Q2 • 25
$50.6M
$13.1M
25.94%
Q3 • 25
68.73%
-3.21%
-42.63%
QoQ growth
QuarterlyAnnual
Operating
info
Investing
info
Financing
info
Free cash flow
info
$-8.4M
$-0M
$11M
$-8.4M
Q2 • 25
$-6M
$-0M
$26.3M
$-6M
Q3 • 25
-29.19%
-66.67%
139.73%
-29.22%
QoQ growth
QuarterlyAnnual

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a Unicycive Therapeutics Inc share?
Collapse

Unicycive Therapeutics Inc shares are currently traded for undefined per share.

How many shares does Unicycive Therapeutics Inc have?
Collapse

Unicycive Therapeutics Inc currently has 21.5M shares.

Does Unicycive Therapeutics Inc pay dividends?
Collapse

No, Unicycive Therapeutics Inc doesn't pay dividends.

What is Unicycive Therapeutics Inc 52 week high?
Collapse

Unicycive Therapeutics Inc 52 week high is $11.00.

What is Unicycive Therapeutics Inc 52 week low?
Collapse

Unicycive Therapeutics Inc 52 week low is $3.71.

What is the 200-day moving average of Unicycive Therapeutics Inc?
Collapse

Unicycive Therapeutics Inc 200-day moving average is $5.30.

Who is Unicycive Therapeutics Inc CEO?
Collapse

The CEO of Unicycive Therapeutics Inc is Dr. Shalabh K. Gupta M.D., MPA.

How many employees Unicycive Therapeutics Inc has?
Collapse

Unicycive Therapeutics Inc has 22 employees.

What is the market cap of Unicycive Therapeutics Inc?
Collapse

The market cap of Unicycive Therapeutics Inc is $124M.

What is the P/E of Unicycive Therapeutics Inc?
Collapse

The current P/E of Unicycive Therapeutics Inc is null.

What is the EPS of Unicycive Therapeutics Inc?
Collapse

The EPS of Unicycive Therapeutics Inc is -$3.44.

What is the PEG Ratio of Unicycive Therapeutics Inc?
Collapse

The PEG Ratio of Unicycive Therapeutics Inc is null.

What do analysts say about Unicycive Therapeutics Inc?
Collapse

According to the analysts Unicycive Therapeutics Inc is considered a buy.